3 years ago

Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan

Hidenori Toyoda, Masanori Atsukawa, Koichi Takaguchi, Tomonori Senoh, Kojiro Michitaka, Atsushi Hiraoka, Shinichi Fujioka, Chisa Kondo, Tomomi Okubo, Haruki Uojima, Toshifumi Tada, Hirohito Yoneyama, Tsunamasa Watanabe, Toru Asano, Toru Ishikawa, Hideyuki Tamai, Hiroshi Abe, Keizo Kato, Kunihiko Tsuji, Chikara Ogawa, Noritomo Shimada, Etsuko Iio, Akihiro Deguchi, Ei Itobayashi, Shigeru Mikami, Akio Moriya, Hironao Okubo, Joji Tani, Akihito Tsubota, Yasuhito Tanaka, Tsutomu Masaki, Katsuhiko Iwakiri, Takashi Kumada

Abstract

Background

The real-world virological efficacy and safety of an interferon (IFN)-free direct-acting antiviral (DAA) therapy with elbasvir (EBR) and grazoprevir (GZR) were evaluated in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1.

Methods

The rate of sustained virologic response (SVR) and safety were analyzed in patients who started the EBR/GZR regimen between November 2016 and July 2017. SVR rates were compared based on patient baseline characteristics.

Results

Overall, 371 of 381 patients (97.4%) achieved SVR. Multivariate analysis identified a history of failure to IFN-free DAA therapy and the presence of double resistance-associated substitutions (RASs) in HCV non-structural protein 5A (NS5A) as factors significantly associated with failure to EBR/GZR treatment. The SVR rates of patients with a history of IFN-free DAA therapy and those with double RASs were 55.6 and 63.6%, respectively. In all other subpopulations, the SVR rates were more than 90%. There were no severe adverse events associated with the treatment.

Conclusions

The EBR/GZR regimen yielded high virological efficacy with acceptable safety. Patients with a history of failure to IFN-free DAA therapy or with double RASs in HCV-NS5A remained difficult to treat with this regimen.

Publisher URL: https://link.springer.com/article/10.1007/s00535-018-1473-z

DOI: 10.1007/s00535-018-1473-z

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.